China SXT Pharmaceuticals, Inc. (SXTC) Operating margin 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) operating margin by fiscal year — reported operating income divided by reported revenue.
-625.9%FY2026 · since FY2017: 32.8% → -625.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -625.9% | -471.9 pp |
| FY2025 | -154.0% | -23.5 pp |
| FY2024 | -130.4% | +154.0 pp |
| FY2023 | -284.4% | -85.0 pp |
| FY2022 | -199.4% | -153.4 pp |
| FY2021 | -46.0% | -20.0 pp |
| FY2020 | -26.0% | -51.2 pp |
| FY2019 | 25.2% | +2.0 pp |
| FY2018 | 23.3% | -9.6 pp |
| FY2017 | 32.8% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SXTC financial trends
SXTC RevenueSXTC Net incomeSXTC Net marginSXTC Gross profitSXTC Gross marginSXTC Operating incomeSXTC Operating cash flowSXTC Free cash flowSXTC Capital expendituresSXTC Return on equitySXTC Stock buybacksSXTC Dividends paidSXTC Total assetsSXTC Total liabilitiesSXTC Shareholders’ equitySXTC overview →